Statistics from Altmetric.com
We read with great interest the report by Raftery et al on Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost-effectiveness. The authors raise the very pertinent point in respect to a single company owning two competing drugs and the inherent cost to tax payers. The authors conclude their abstract with “Public pressure may be the most potent weapon in persuading Genentech to license bevacizumab for AMD.” We would like to suggest what forms this public pressure may …
Competing interests: None.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.